European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices1556
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?226
Striving for the ‘perfect’ definition of iron deficiency in heart failure148
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’137
135
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail130
Heart failure: age is no excuse for complacency121
Dissecting the heart failure phenotype through phenomics120
Issue Information111
Risk factors for the development of heart failure in patients with or without prior myocardial infarction109
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival103
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES103
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials99
Abstract99
Issue Information93
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial91
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial79
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction77
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold76
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair72
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up67
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices66
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock66
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’63
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management63
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial62
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure60
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h60
Abstract59
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF59
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE59
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials59
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology57
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases57
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial56
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians55
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure 55
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC55
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery55
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial54
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology54
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters53
Issue Information53
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato53
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities52
Issue Information52
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction52
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models51
Use of mechanical circulatory support in patients with non‐ischaemic cardiogenic shock51
The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial51
51
The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis51
0.14610600471497